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health care costs among type 2 diabetes patients. METHODS:
A pre-post conversion approach was adopted using an integrated
medical and pharmacy claims database from >50 managed care
health plans in the United States. Adults diagnosed with type 2
diabetes who converted to insulin pen therapy (FlexPenTM) from
either human or analog insulin vials between July 2001 and
December 2002 with no prior use of FlexPenTM for six months
were identiﬁed and retrospectively analyzed. Endpoints included
adherence (medication possession ratio (MPR)), follow-up time
adjusted odds ratio of hypoglycemic events, association between
adherence and hypoglycemic events in a Poisson multivariate
context, and diabetes-attributable (DA) and hypoglycemia-
attributable (HA) costs. RESULTS: A total of 1156 subjects were
identiﬁed and included (mean age 45.4 + 13.7; 51.5% previously
on human insulin vials). Post-conversion, adherence improved
signiﬁcantly (MPR: 69% vs. 62%; p < 0.01). Additionally, fewer
hypoglycemic events were observed [OR: 0.50 (CI: 0.37–0.68);
p < 0.05] and such events requiring either emergency department
visits and physician visits decreased by 56% [OR: 0.44 (CI:
0.21–0.92)] and 61% [0.39 (CI: 0.24–0.64)], respectively (p <
0.05). Incidence of hypoglycemic events in subjects with MPR >
70% as conﬁrmed by a Poisson multivariate analysis, dropped
by nearly two-thirds [0.35 (0.11–0.81); p < 0.05]. Total annual
HA costs fell 56% ($1415 vs. $627; p < 0.01), and total DA
costs fell 7% ($8827 vs. $8227; p < 0.01). CONCLUSIONS:
Converting to insulin pen therapy from administration with
vial/syringe was associated with improved adherence, which in
turn was correlated with fewer hypoglycemic events and lower
treatment costs among type 2 diabetes patients. Future studies
should examine the impact of earlier use of insulin pen therapy
on patient adherence as well as clinical and economic outcomes.
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OBJECTIVES: Comparisons of “real world” effectiveness of dia-
betes treatments within a single population are rare. We com-
pared glycemic response after the addition of any of the four
most commonly used therapeutic classes (metformin, sul-
fonylureas, insulin, thiazolidinediones) for type 2 diabetes.
METHODS: We studied 15,126 type 2 diabetes patients initiat-
ing a single new ntihyperglycemic therapeutic class (new user
design) in 1999–2000 in Kaiser (health plan in USA). In
ANCOVA models, we assessed pre-post (3–12 months after ini-
tiation) change in glycosylated hemoglobin (A1C), adjusted for
baseline A1C, other antihyperglycemic therapy, demographics,
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Switching from oral antidiabetics to insulin injection is perceived
as a major barrier by diabetes mellitus type-2 patients with fear
for injection of insulin, but little is known about the extent.
OBJECTIVE: To estimate the rate of starting insulin in newly
identiﬁed diabetes mellitus patients, in patients starting with a
combination of two oral antidiabetics and in patients with
uncontrolled HBA1c levels while taking two oral antidiabetic
agents. METHODS: A retrospective cohort study was conducted
in the IPCI general practice database during the period
1996–2004. Patients with diabetes mellitus type II (DM-2) were
classiﬁed as prevalent if DM-2 was diagnosed prior to entry in
follow-up and as incident if diagnosed during follow-up. Three
cohorts were identiﬁed to assess the rate and risk of starting
insulin. Cohort A: all incident DM-2 patients, cohort B: all
patients newly starting with a multiple pill oral combination
therapy. Cohort C was a subset of B and comprised all patients
on oral combination therapy who had uncontrolled HBA1c
levels after at least 3 months of treatment. RESULTS: The source
population comprised 5693 incident and 7456 prevalent DM-2
patients. In incident DM-2 patients 80% was treated pharma-
cologically within one year, 3% received an insulin based
regimen as initial treatment, 76% started on a single oral antidi-
abetic. The rate of starting insulin was 0.6/100 PY in patients of
cohort A, who started on oral treatment. The rate of starting
insulin was 6.6/100 PY for patients in cohort B (n = 1858). The
one-year risk of starting insulin in cohort C (n = 1167) was 3.8%
(2.1–5.5%) for patients with HBA1c between 7–8% and 14.3%
for patients with HBA1c above 8% at cohort entry. CONCLU-
SION: The rates and one-year risks of starting insulin are low
even in DM-2 patients who remain uncontrolled after at least
three months of oral combination therapy.
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OBJECTIVE: This study sought to evaluate the impact of con-
verting to insulin administration with an analog insulin pen
device from vial/syringe on adherence, hypoglycemic events, and
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